First Time Loading...
N

NeoPharm Co Ltd
KOSDAQ:092730

Watchlist Manager
NeoPharm Co Ltd
KOSDAQ:092730
Watchlist
Price: 29 550 KRW -0.51% Market Closed
Updated: Jun 8, 2024

NeoPharm Co Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

NeoPharm Co Ltd
Cost of Revenue Peer Comparison

Comparables:
090430
002790
192820
051900
161890

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
N
NeoPharm Co Ltd
KOSDAQ:092730
Cost of Revenue
-₩35.4B
CAGR 3-Years
-13%
CAGR 5-Years
-13%
CAGR 10-Years
-21%
AmorePacific Corp
KRX:090430
Cost of Revenue
-₩1.1T
CAGR 3-Years
5%
CAGR 5-Years
5%
CAGR 10-Years
-2%
Amorepacific Group
KRX:002790
Cost of Revenue
-₩1.1T
CAGR 3-Years
7%
CAGR 5-Years
7%
CAGR 10-Years
1%
Cosmax Inc
KRX:192820
Cost of Revenue
-₩1.6T
CAGR 3-Years
-10%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
LG H&H Co Ltd
KRX:051900
Cost of Revenue
-₩3.2T
CAGR 3-Years
-2%
CAGR 5-Years
-3%
CAGR 10-Years
-5%
Kolmar Korea Co Ltd
KRX:161890
Cost of Revenue
-₩1.6T
CAGR 3-Years
-19%
CAGR 5-Years
-9%
CAGR 10-Years
-18%

See Also

What is NeoPharm Co Ltd's Cost of Revenue?
Cost of Revenue
-35.4B KRW

Based on the financial report for Mar 31, 2024, NeoPharm Co Ltd's Cost of Revenue amounts to -35.4B KRW.

What is NeoPharm Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-21%

Over the last year, the Cost of Revenue growth was -30%. The average annual Cost of Revenue growth rates for NeoPharm Co Ltd have been -13% over the past three years , -13% over the past five years , and -21% over the past ten years .